Press Release
March 1, 2018

Rubius Therapeutics Closes $100 Million Financing

The Life Sciences team represented Rubius Therapeutics in its successful completion of a $100 million crossover financing. In just under nine months, Rubius has raised over $220 million.

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics™ (RCT™) products, which have the potential to provide transformational clinical benefits to a wide range of patients across multiple therapeutic areas. Proceeds from the financing will be used to accelerate the development of the company’s portfolio of RCTs™ towards clinical proof-of-concept, and to enhance its manufacturing capacity and capabilities.

The Goodwin team was led by partners Stuart Cable and associate Sarah Ashfaq.

For more details on the financing, please read the press release.